Clinical Trial Update: Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects. [Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 2 trial evaluating CP-866,087 for reducing alcohol consumption and cravings in alcohol use disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcohol Use Disorder

Drugs mentioned

• CP-866,087

Snippet

Sponsor: Pfizer | Conditions: Alcoholism | Phase 2 | Status: COMPLETED